WOODRIDGE, Ill., Nov. 4 /PRNewswire/ -- Flavin Ventures has announced the start up and funding of its first new biotechnology venture since its recent establishment. Flavin Ventures has helped launch Shamrock Structures, a Chicago-based structural proteomics company, that will offer integrated services in structural proteomics including protein cloning, expression, purification and crystallization. Shamrock Structures will enable pharmaceutical and biotechnology clients to reduce the time it takes to advance from protein targets to new drugs.
Structural proteomics capabilities are valuable to clients in the design and discovery of novel drug therapies to treat life-threatening diseases. Shamrock Structures is offering these services through a special agreement with the Structural Biology Center at Argonne National Laboratory. Shamrock Structures provides clients with integrated structural proteomics services including rapid access to the Advanced Photon Source (APS), one of the few third generation X-ray synchrotron sources in the world.
“Shamrock’s agreement with Argonne’s Structural Biology Center gives its clients access to the most advanced technologies the science of structural proteomics currently has to offer,” said John Flavin, managing director of Flavin Ventures. “The Argonne relationship will provide a platform from which Shamrock can enable clients to identify and develop new drug targets more rapidly and significantly reduce the timeline from protein target to lead drug compound.”
“Our agreement with Shamrock Structures will allow us to more easily deliver Argonne’s powerful structural proteomics technologies to the marketplace,” said Andrej Joachimiak, PhD, head of the Structural Biology Center at Argonne National Laboratory. “Our world-class team’s track record in protein structure determination and cutting edge tools allow us to effectively shorten the timeframe from protein target to lead drug generation providing our clients with more precise and cost effective drug leads.”
Shamrock Structures LLC, based in Woodridge, IL, is a privately held structural proteomics company. Through its agreement with Argonne’s Structural Biology Center, Shamrock offers clients in the pharmaceutical and biotechnology industries rapid access to protein structures and lead drug generation capabilities. ( http://www.shamrockstructures.com/ )
Flavin Ventures, LLC is an early stage venture capital and management group for innovative Midwestern life sciences companies focused on drug discovery. In addition to Shamrock Structures, Flavin Ventures currently has investments in biopharmaceutical companies Advanced Life Sciences ( http://www.advancedlifesciences.com/ ) and Sarawak MediChem Pharmaceuticals ( http://www.sarawak-medichem.com/ ).
America’s first national laboratory, Argonne is operated by the University of Chicago as part of the U.S. Department of Energy’s national laboratory system. ( http://www.anl.gov/ ).
Flavin Ventures
CONTACT: Media, Gail Cowan, +1-773-782-3909, or Investor, John Flavin,+1-630-739-6744, both of Flavin Ventures
